Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
about
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionMutant prevention concentration, pharmacokinetic-pharmacodynamic integration, and modeling of enrofloxacin data established in diseased buffalo calves.A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels?In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceA population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacyComputational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection modelPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Editorial Comment to Postoperative infectious complications in patients undergoing holmium laser enucleation of the prostate: Risk factors and microbiological analysis.Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killMathematical model on Alzheimer's diseaseUsing Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Emerging drugs on methicillin-resistant Staphylococcus aureus.Treatment option for sepsis in children in the era of antibiotic resistance.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis.Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro InformationNecessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.Translational PK/PD of anti-infective therapeutics.Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy.Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline-free acid following subcutaneous administration in domestic goats.Activity of cefquinome against extended-spectrum β-lactamase-producing Klebsiella pneumoniae in neutropenic mouse thigh model.Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.Biofilm formation and antibiotic susceptibility in dispersed cells versus planktonic cells from clinical, industry and environmental origins.Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.In vivo activity of cefquinome against Riemerella anatipestifer using the pericarditis model in the duck.Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.Pharmacokinetics and residue depletion of erythromycin in gilthead sea bream Sparus aurata L. after oral administration.Pharmacokinetics and residue depletion of erythromycin in rainbow trout Oncorhynchus mykiss (Walbaum).Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
P2860
Q26753831-6D6FBC0D-D10E-46DB-B2CF-B619962B9149Q30911044-79312BFE-7EC4-4631-B259-274A683B2577Q31059319-6856C419-5A23-49F8-BFDB-20ABB04A0184Q33905531-0B4CCF21-1BCC-448D-BDE0-3BB6F9AA726FQ34299028-957AEA55-DBEE-423A-8450-DA4DB0A3E1D6Q34596526-615CBF28-0B77-406C-9592-776D91E9A195Q35169043-0671C2A7-C474-41ED-8809-2FB1D94D3C07Q35864589-43EA8CBB-53AF-4D79-A4E0-A493FCFC65E9Q36083619-F9D242CE-28F4-437F-A78D-B63783861245Q36109394-47C9E6D8-18C8-4F0A-84E4-BAC7D36F0F26Q36171772-8E27E7F3-2D1F-4296-9A0D-12871FFC072EQ36198218-598DB6E7-6460-4D97-A7D6-39FC706CE3D7Q36242447-349215CB-7C4E-4A98-9FB3-B1C32C4FAC2FQ36383878-F0628DA9-4B41-47D4-A87A-0336DDF7BCC5Q36413575-9D0771B1-920C-420B-ADCD-61B1EB6B6E39Q36684146-9291ABE7-21F8-4799-9006-EE50C8BAAF1DQ38121142-14D204C0-4A0D-45E1-8D1F-C62752BF1E5CQ38246118-4B39339B-01B0-426A-AFA9-29A22B31DB23Q38420688-D6D29D2A-73D0-4C8C-A1A6-4C3BC327F0AEQ38664871-DA148B7E-3FC3-47C6-8E4D-9C6B4FE9B262Q38699731-C582267A-568B-4E51-9FE2-66DD80D80347Q38786623-0B684F80-9820-4D42-A1CB-82B2C44E3BB6Q38853629-9C283847-A1C4-4C5F-A8E3-1BB11A6834D9Q38880229-CCFECEA9-CAEB-476F-A9D8-3395CA21DF8DQ38966188-7E7B9565-3358-4741-BC33-D3CF340C124FQ39019096-1C50052A-A2B5-428C-90A4-376F3E2F7AEEQ39039505-6840849B-1885-4CFE-8BFB-ECDF320BBDAFQ39071799-0DF2A2B2-1EA7-41C3-91ED-8D3C5512291DQ39108922-F9A95696-B9BD-4D9E-97DE-D240EDBF4758Q39451172-9EE157E6-985F-4EE9-9FF0-66414000411AQ40087805-6BFAB244-F6C5-485E-A806-939A8BEE5571Q40108765-8791106E-3D6B-4B25-9299-063538813162Q40326667-3B141E6F-170A-4B27-8765-FD5A23E3F4E0Q40330083-43943C43-046A-44A4-B173-F2D09A74C93CQ40857961-2F6033EB-B5B6-4517-862B-691937438F29Q41967888-330BEE7A-153F-43F7-AED7-538618583A52Q44361727-4735571A-97B7-4CE8-8467-2AEBD0FE9441Q46983972-447EFFAE-0949-47F7-8C85-98917497ED63Q47236751-D4297AD7-57A2-4050-B62C-2B407076D7F1Q47273930-9C2FF13A-6F0C-47E1-AB75-E04B9BB79973
P2860
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacokinetic/pharmacodynami ...... model-based dose optimization.
@en
type
label
Pharmacokinetic/pharmacodynami ...... model-based dose optimization.
@en
prefLabel
Pharmacokinetic/pharmacodynami ...... model-based dose optimization.
@en
P2093
P2860
P356
P1476
Pharmacokinetic/pharmacodynami ...... model-based dose optimization.
@en
P2093
Elisabet I Nielsen
Lena E Friberg
P2860
P304
P356
10.1128/AAC.00182-11
P407
P577
2011-08-01T00:00:00Z